In a recently completed Phase 3, double-blind, randomized, controlled trial of once-weekly tirzepatide in the treatment of obesity, tirzepatide 15 mg achieved a mean percentage change in body weight of -20.9% (-21.9 kg) over 72 weeks of treatment, suggesting that tirzepatide 15 mg is also a potential weight loss agent ( Semaglutide1.0mg and oral semaglutide 14mg was inferior to tirzepatide in reducing HbA1c and body weight but had significant advantages over other GLP-1RAs
Presented for research literature review only Castro AM et al
Ranging from cell proliferation, cell differentiation and apoptosis, tissue growth, and organ-specific functions, the biological functions of IGF-1 and its measurement have been deemed significant
Median follow-up times were 642 days and 529 days in the GLP-1RA and DPP-4i group, respectively
Redox Biol 6:198205
Comparison with human growth hormone Comparing IGF-1 LR3 to HGH reveals why the medical establishment embraces one while shunning the other